Ipca Laboratories Ltd
🇰🇪Kenya
- Country
- 🇰🇪Kenya
- Ownership
- Public
- Established
- 1949-01-01
- Employees
- 22.8K
- Market Cap
- $4.2B
- Website
- http://www.ipca.com
Clinical Trials
44
Active:0
Completed:34
Trial Phases
3 Phases
Phase 1:30
Phase 3:12
Phase 4:2
Drug Approvals
27
PHILIPPINES:27
Drug Approvals
- Prev
- 1
- 2
- 3
- Next
Clinical Trials
Distribution across different clinical trial phases (44 trials with phase data)• Click on a phase to view related trials
Phase 1
30 (68.2%)Phase 3
12 (27.3%)Phase 4
2 (4.5%)Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 50 mg
Phase 1
Completed
- Conditions
- Fasting
- Interventions
- Drug: 'TOPROL-XL®' ER Tablets 50 mg
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- IPCA Laboratories Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT01884857
- Locations
- 🇮🇳
Cliantha Research Limited, Ahmedabad, Gujarat,, India
Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fasting Conditions
Phase 1
Completed
- Conditions
- Fasting
- Interventions
- Drug: 'TOPROL-XL®' ER Tablets 200 mg
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- IPCA Laboratories Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT01884896
- Locations
- 🇮🇳
Cliantha Research Limited, Ahmedabad, Gujarat, India
Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fed Conditions
Phase 1
Completed
- Conditions
- Fed
- Interventions
- Drug: 'TOPROL-XL®' ER Tablets 200 mg
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- IPCA Laboratories Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT01884909
- Locations
- 🇮🇳
Cliantha Research Limited, Ahmedabad, Gujarat, India
Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fed Condition
Phase 1
Completed
- Conditions
- Fasting
- Interventions
- Drug: GLUCOPHAGE®XR tablet 750 mg
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2013-04-15
- Lead Sponsor
- IPCA Laboratories Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT01831674
- Locations
- 🇮🇳
Veeda Clinical Research Pvt. Ltd., Ahmedabad, Gujarat, India
Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fed Condition
Phase 1
Completed
- Conditions
- Fasting
- Interventions
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2013-04-15
- Lead Sponsor
- IPCA Laboratories Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT01831687
- Locations
- 🇮🇳
Veeda Clinical Research Pvt. Ltd., Ahmedabad, Gujarat, India
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found